FDA Clears Ultragenyx's UX016 IND for Rare GNE Myopathy, Externally Funded Through Phase 1/2
Summary
Ultragenyx announced that the FDA has cleared its Investigational New Drug (IND) application for UX016, a sialic acid prodrug for the treatment of GNE Myopathy, a rare neuromuscular disorder. This is a positive development for Ultragenyx, especially following the recent negative news regarding the failure of its Phase 3 UX143 study and an Incomplete Response Letter for its UX111 gene therapy BLA. Notably, the UX016 program is externally funded through clinical proof-of-concept, including the planned Phase 1/2 study expected to begin in the second half of 2026, which significantly de-risks early development for the company. This adds a new, promising candidate to Ultragenyx's pipeline, addressing a high unmet medical need. Investors will now watch for the initiation and initial data from the Phase 1/2 study.
At the time of this announcement, RARE was trading at $18.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $18.29 to $42.37. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.